Core Insights - Wayfair's shares surged 23.6% this week following a strong third-quarter earnings report, showcasing solid revenue growth and a significant increase in adjusted earnings per share [1] Revenue Performance - Total revenue increased by 8.1% year over year to $3.1 billion; without the exit from the German market, growth would have been 9% [3] - U.S. revenue, which constitutes the majority of total revenue, grew by 8.6%, while international revenue rose by 4.6% [3] Customer Metrics - The customer base decreased to 21.2 million, down 2.3% year over year; however, the number of orders increased by 5.4% compared to the previous year [4] - The average order size grew to $317 from $310 a year ago, with over 80% of orders coming from repeat customers [4] Profitability and Financial Metrics - Wayfair reported adjusted earnings per share of $0.70, more than tripling from the prior year; adjusted EBITDA rose 75% to $208 million, and operating cash flow more than tripled [5] - Despite these positive metrics, the company remains unprofitable on a GAAP basis, although GAAP operating income was positive during the quarter [7] Market Conditions and Future Outlook - The strong results were unexpected given the challenges posed by a sluggish housing market and tariffs affecting consumers [6] - The sustainability of Wayfair's performance is uncertain due to ongoing tariff issues and unpredictable economic conditions [7]

Core Insights - Comcast Corporation reported better-than-expected third-quarter earnings with adjusted earnings per share of $1.12, exceeding analyst expectations by $0.02 [1] - Revenue declined 2.7% year-over-year to $31.2 billion but surpassed the consensus estimate of $30.7 billion [1] - Adjusted EBITDA decreased by 0.7% to $9.7 billion [1] Revenue Breakdown - The revenue decline was attributed to tough comparisons with last year's results, which included contributions from the Paris Olympics [2] - The wireless business added a record 414,000 lines, growing domestic wireless revenue by 14% to $1.25 billion, partially offsetting broadband customer losses of 104,000 [2] Segment Performance - Theme Parks revenue surged 18.7% to $2.7 billion following the successful May opening of Epic Universe in Orlando [3] - The Studios division reported a 6.1% revenue increase to $3 billion, driven by the blockbuster performance of Jurassic World Rebirth, which generated nearly $900 million globally [3] - Business Services continued to perform well, with connectivity revenue up 6.2% to $2.6 billion and EBITDA rising 4.5% to $1.5 billion [3]

Financial Data and Key Metrics Changes - Core FFO for Q3 2025 was $2.08 per share, meeting internal expectations [4] - Same-store occupancy at quarter-end was 93.7%, with an average of 94.1% during the quarter, a 30 basis point improvement year over year [4] - Same-store revenue declined 0.2% year over year, slightly below internal forecasts [10] - Same-store new customer rate growth was approximately 6% excluding discounts, while net growth was over 3% year over year [5][10] - Full-year core FFO guidance raised to a range of $8.12 to $8.20 per share based on year-to-date performance [12] Business Line Data and Key Metrics Changes - The third-party management platform expanded by 95 stores during the quarter, with a total managed portfolio of 1,811 stores [7] - The bridge loan program originated $123 million during the quarter, with $71 million in mortgage loans sold [6] Market Data and Key Metrics Changes - The self-storage sector continues to show resilience, with a geographically diversified portfolio of over 4,200 stores across 43 states [13] - Same-store expenses were above internal estimates, driven by repairs and maintenance and marketing expenses [11] Company Strategy and Development Direction - The company is focusing on long-term revenue optimization through strategic discounts, despite short-term headwinds [5] - Increased acquisition guidance to $900 million, driven by a $244 million purchase of a 24-property portfolio [6] - The company maintains a conservative capital structure with 95% of interest rates fixed [11] Management's Comments on Operating Environment and Future Outlook - Management expects same-store revenue to remain relatively flat for 2025, but is optimistic about outside growth in other revenue streams [9] - The company is encouraged by the sustained positive rate trend and believes it is well-positioned for accelerating revenue growth [10][13] - Management is positive about the future, citing improving rent rate trends and decreasing supply [98] Other Important Information - The company has been actively testing discounting strategies to maximize long-term revenue, particularly in states with emergencies [18][63] - The bridge loan program is expected to benefit from a lower-rate environment, providing a countercyclical growth opportunity [70] Q&A Session Summary Question: How long does new customer rate growth take to impact same-store revenue growth? - Management indicated that the timing depends on churn and other factors, but they are encouraged by the accelerating trend in new customer rates [16][17] Question: Has the discounting strategy continued into October? - Management confirmed that they have been using discounts strategically and are testing their effectiveness [18][19] Question: What specific regions were affected by the discounting strategy? - The discounting efforts were focused on states with emergencies, such as Los Angeles [23] Question: What is the outlook for the bridge loan program in a lower-rate environment? - Management expects the lower-rate environment to positively impact the bridge loan program, as it may loosen the acquisition market [70][71] Question: How does the company view its marketing spend efficiency? - Management stated that they have not seen a decline in the ROI of their marketing spend and view it as an investment [32][33] Question: What is the expected impact of the recent acquisition on yields? - The acquisition is expected to have a leverage yield of about 4.5% in year one, increasing to mid-7% by year three [27] Question: How does the company plan to manage expenses moving forward? - Management emphasized the importance of investing in properties and personnel to maximize long-term revenue while being efficient [35][36]

Core Insights - Cardinal Health, Inc. reported first-quarter fiscal 2026 adjusted earnings per share (EPS) of $2.55, exceeding the Zacks Consensus Estimate of $2.21 by 15.4%, and showing a year-over-year improvement of 35.6% [1][8] - Total revenue for the quarter reached $64 billion, marking a 22% increase year over year and surpassing the Zacks Consensus Estimate by 8.4% [2][8] Revenue Details - Sales increased by 22% year over year to $64 billion, beating estimates [2] Segmental Analysis - **Pharmaceutical and Specialty Solutions**: Revenues rose 23% to $59.2 billion, driven by growth in branded and specialty pharmaceutical sales [3] - **Pharmaceutical Profit**: Totaled $667 million, up 26% from the previous year, supported by brand and specialty products [4] - **Global Medical Products and Distribution**: Revenues reached $3.2 billion, a 2% increase year over year, with profits rising from $8 million to $46 million [4] - **Other Segment**: Sales grew 38% to $1.6 billion, with profits increasing 60% to $166 million, driven by strong performance across its operating segments [5] Margin Analysis - Gross profit increased 22% year over year to $2.32 billion, with a gross margin of 3.6% [6] - Distribution, selling, general and administrative expenses rose 14% to $1.46 billion [6] - Operating income was $668 million, an 18% increase year over year, with adjusted operating income up 37.1% to $857 million [6] Financial Update - The company ended the quarter with cash and cash equivalents of $4.59 billion, up from $3.87 billion in the previous quarter [9] - Net cash provided by operating activities was $973 million, compared to $1.65 billion used in the same period last year [9] 2026 Outlook - Cardinal Health raised its fiscal 2026 earnings guidance, expecting adjusted EPS between $9.65 and $9.85, up from a prior outlook of $9.30-$9.50 [10] - Projected revenue growth for the Pharmaceutical segment is 11-13%, with segment profit expected to increase 16-19% [10][11] - Medical segment revenues are estimated to grow 2-4%, while the Other segment is expected to see revenue growth of 26-28% [11] Conclusion - The company reported strong first-quarter results, with broad-based profit growth across all segments, particularly in Pharmaceutical and Specialty Solutions [12] - The positive results led to a 10% increase in shares during pre-market trading, with a year-to-date gain of 39.1% compared to the industry’s 4.1% [13]

Core Insights - The company experienced significant gross margin expansion, increasing to 88% from 71%, which represents a 17-point improvement [1] - The operating loss was reduced by 65%, narrowing to $439,000 from $1.25 million in 2024 [1]

Business Performance - IntrCity SmartBus revenue grew by 67% last year [1] - The company is targeting full profitability this year [1] Market Trend - Intercity travel is booming across India [1]

Revenue and Expense Growth - Meta's revenue growth is expected to be around 18% next year, higher than the street's expectation of 16% [3][4][13] - Meta's expense growth is projected to be north of 30% [4] - In the September quarter, Meta's revenue growth was 23%, while expense growth was 32% [3] - In 2024, Meta's revenue growth was about 23%, and expense growth was about 8% [2] - In the first two quarters of this year, Meta's revenue growth was 22%, and expense growth was 12% [2] Capital Expenditure (Capex) and AI Investment - Meta is aggressively increasing expenses related to third-party capex spend [3] - Meta's CEO is setting the company up to be the most optimistic regarding AI, evidenced by the increase in capex [7] - Meta is building its AI infrastructure for the most optimistic case [9] - Google is guiding up their capex to be up like 25% next year, similar to Microsoft and Amazon [8] User Engagement - 43% of the world uses Meta's products on a daily basis, and the rate of usage is accelerating [4] Market Expectations and Stock Performance - The street is looking for 40% growth for Meta in 2026, but it's probably going to be up more than 60% [8] - Investors are recalibrating Meta's stock due to the shift in expense growth [7] - Meta needs to show improvement in the December quarter, with revenue growth higher and expenses lower than expected [12] - Meta needs to continue demonstrating that AI is driving revenue growth [13]

Financial Data and Key Metrics Changes - Bausch Health reported a year-over-year revenue growth of 7% on a reported basis and 5% on an organic basis, achieving $2.681 billion in revenue for the third quarter [4][8] - Adjusted EBITDA increased by 8% year-over-year to $986 million, with an adjusted gross margin of 72.7%, which is 40 basis points lower than the previous year [8][9] - The company reduced its debt by approximately $600 million, leading to an increase in full-year guidance for revenue, adjusted EBITDA, and adjusted operating cash flow [5][15] Business Line Data and Key Metrics Changes - The Solta Medical segment saw a remarkable 25% growth on a reported basis and 24% on an organic basis, while Salix delivered 12% growth on a reported basis and 11% on an organic basis [6][10] - Xifaxan revenue grew 16% in the third quarter, with volume up 9%, driven by strong performance in the hepatology segment [10][20] - The diversified segment experienced a revenue decrease of 4% on a reported basis and 6% on an organic basis, primarily due to challenges in the neurology business [13][14] Market Data and Key Metrics Changes - International segment revenues decreased by 2% on a reported basis and 4% on an organic basis, with mixed performance across geographies [11] - EMEA led the international segment with a 12% increase, while Canada and LATAM contracted by 8% and 17%, respectively [11] - The Asia-Pacific region contributed significantly to Solta Medical's growth, with South Korea achieving 96% growth year-over-year [12][22] Company Strategy and Development Direction - The company is focused on five strategic priorities: people, growth, efficiency, innovation, and unlocking value, which guide its vision for the future [18] - Bausch Health aims to enhance its operational assets and continue executing its innovation and profitable growth agenda [16][18] - The acquisition of DURECT Corporation is expected to complement the existing portfolio and enhance the R&D pipeline, particularly in hepatology [24][25] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in navigating a dynamic macro backdrop and highlighted strong operational performance [5][18] - The company anticipates continued growth in its key segments, particularly in Xifaxan and Solta Medical, while also preparing for the impact of CMS pricing negotiations [19][33] - Full-year guidance has been raised, reflecting positive trends across the portfolio, with revenue expected between $5 billion and $5.1 billion [15][16] Other Important Information - The company exited the 340B program and Medicaid drug rebate program to optimize sales channels and enhance patient assistance programs [61][62] - The focus remains on deleveraging the business and optimizing the capital structure, with plans to use free cash flow for debt servicing [66][68] Q&A Session Summary Question: Revenue growth for Xifaxan outpacing script growth - Management explained that the disconnect is due to a one-time benefit associated with gross-to-net accrual and strong new patient starts [30][32] Question: Dynamics of CMS pricing negotiations - Management confirmed ongoing fruitful negotiations with CMS and expects pricing to be published on November 30, 2025 [33][34] Question: Revised guidance and one-time factors - Management acknowledged one-time adjustments in Q3 but emphasized positive trends across the portfolio [40][41] Question: SG&A spending and future run rates - Management indicated that Q3 SG&A was unusually low due to non-recurring accrual changes, suggesting Q1 and Q2 as better indicators for future spending [42][43] Question: RED-C phase 3 results timeline - Management confirmed that both phase 3 studies will have a combined readout in early 2026, which will be the final readout for the program [45][46] Question: Impact of exiting the 340B program - Management highlighted the decision was made to optimize sales channels and enhance patient assistance programs [62][63] Question: Debt refinancing and deleveraging strategies - Management outlined plans to use free cash flow for debt servicing and mentioned potential asset sales as a means to support deleveraging [66][68]

Core Viewpoint - Clean Harbors experienced a significant stock sell-off of over 11% following the release of its third-quarter results, which underperformed market expectations [1]. Financial Performance - The company reported third-quarter revenue of $1.55 billion, reflecting a year-over-year growth of just over 1% [2]. - Net income for the quarter was $118.8 million, or $2.21 per share, which was only slightly above the previous year's profit of $115.2 million [2]. - Both revenue and net income figures fell short of analyst expectations, which were $1.57 billion for revenue and $2.40 per share for net income [3]. Guidance Revision - Clean Harbors revised its full-year 2025 guidance, lowering its forecast for non-GAAP adjusted EBITDA to a range of just under $1.16 billion to almost $1.18 billion, down from a previous estimate of $1.16 billion to $1.2 billion [4]. - On a positive note, the company anticipates an increase in adjusted free cash flow, now projected to be between $455 million and $495 million, up from the earlier forecast of $430 million to $490 million [5].

Financial Data and Key Metrics Changes - In Q3 2025, the company generated $157 million in revenue, a 17% increase year over year, and for the first nine months, revenue totaled $740 million, reflecting a 55% increase compared to the prior year [23][24] - The company raised its 2025 financial guidance, now expecting total revenue between $875 million and $900 million, an increase of $50 million from previous guidance [25][26] - Operating loss is anticipated to be between $275 million and $300 million for the full year, with a cash balance expected to exceed $2.1 billion [25][26] Business Line Data and Key Metrics Changes - Tringolsa reported $32 million in net product sales, a nearly 70% increase quarter over quarter [14][23] - Royalty revenues increased by approximately 13% to $76 million in Q3, driven by contributions from Spinraza and Waylivra [24] - Donzera's launch is showing strong early adoption, with initial prescriptions being filled shortly after approval [19][20] Market Data and Key Metrics Changes - The U.S. prophylactic HAE market is well established, with approximately 20% of patients switching treatments annually, indicating a significant opportunity for Donzera [20] - The severe hypertriglyceridemia (SHTG) market is estimated to have over 1 million high-risk patients in the U.S., with Olzarsen positioned to address unmet needs in this population [16][17] Company Strategy and Development Direction - The company is focused on executing its strategy with two independent launches underway and plans for two additional launches next year [27][22] - The advancing wholly owned late-stage pipeline and a robust partnered portfolio are expected to drive sustained growth [7][26] - The company aims to achieve cash flow breakeven by 2028, emphasizing long-term value creation [26] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the continued success of Tringolsa and the upcoming launches of Olzarsen and Zilganersen, highlighting the strong momentum across the business [5][27] - The management team is optimistic about the potential for multi-billion dollar revenue from the new product launches and the overall pipeline [7][25] Other Important Information - Richard Geary, Chief Development Officer, will retire at the end of the year, marking his last earnings call with the company [28] Q&A Session Summary Question: Thoughts on the launch curve for Olzarsen in SHTG - Management indicated strong interest from healthcare providers and plans to target approximately 20,000 HCPs covering around 360,000 patients [30][32] Question: Concerns regarding acute pancreatitis events in Olzarsen studies - Management reassured that the data is groundbreaking and that the acute pancreatitis outcomes will be detailed at the upcoming AHA presentation [36][38] Question: Peak revenue potential for Donzera and Olzarsen - Management expects peak sales for Donzera to exceed $500 million and for Olzarsen to exceed $1 billion [39] Question: Pricing strategy for Olzarsen - Management is still working on pricing and expects to provide more clarity next year [44][45] Question: Early prescriptions for Donzera - The launch is going well, with both switching patients and newly diagnosed patients contributing to early prescriptions [70][72]